Shumei Kato
0000-0003-1193-1815
Publication & Citation Trends
Most Cited Works
Publications
424 total
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations
Cited by 3
Semantic Scholar
Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond
Cited by 0
Semantic Scholar
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations
Cited by 0
Semantic Scholar
Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer
Cited by 0
Semantic Scholar
The predictive role of TRAIL gene expression in immune checkpoint inhibitor (ICI)-treated patients (pts).
Cited by 0
Semantic Scholar
Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection
Cited by 4
Semantic Scholar
CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists
Cited by 1
Semantic Scholar
Toll-like receptor 3: a double-edged sword OA
Cited by 25
Semantic Scholar
Abstract 2044: High TLR3 transcript levels correlate with high TIM3 and VISTA checkpoints, but not with outcome after immune checkpoint blockade
Cited by 0
Semantic Scholar
TLR9: A Double-Dealing Toll-Like Receptor
Cited by 0
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(183)
Cancer Immunotherapy and Biomarkers
(97)
Lung Cancer Treatments and Mutations
(56)
Colorectal Cancer Treatments and Studies
(47)
Genetic factors in colorectal cancer
(47)
Frequent Co-Authors
Affiliations
Mount Sinai Beth Israel
Albert Einstein College of Medicine
Target (United States)
The University of Texas MD Anderson Cancer Center
University of San Diego